Novan, Inc. announced several leadership promotions. These changes further strengthen the alignment of the company’s significant scientific and drug development expertise to its short, intermediate and longer-term opportunities. Paula Brown Stafford has been promoted to President and the newly created role of Chief Operating Officer while remaining a member of the Board of Directors. Ms. Stafford joined Novan in March 2017 as Chief Development Officer. Prior to Novan, she was President of the Quintiles Global Clinical Development organization. Ms. Stafford will continue to report to G. Kelly Martin, Novan’s Chief Executive Officer. Dr. Carri Geer has been promoted to Senior Vice President and Chief Technology Officer of Novan. Dr. Geer will be responsible for integrating formulation and analytical science with clinical translation in order to modify existing molecules and generate new chemical entity (NCE) opportunities. Dr. Geer has more than 10 years of industry experience both from her time at Novan and previously at Merck & Co., Inc. She will report to Ms. Stafford. Dr. Elizabeth Messersmith, Senior Vice President, has been promoted to the role of Chief Development Officer with oversight of the clinical, medical, statistical, and regulatory activities of the Company. Dr. Messersmith has 25 years of hands-on drug development and biotechnology industry experience. She will also report to Ms. Stafford. Dr. Nathan Stasko has stepped down as President and from the Board of Directors, as contemplated by his amended and restated employment agreement to occur following the appointment of Mr. Martin as Chief Executive Officer.